The Price of Flexibility
Executive Summary
Drug companies should not be philanthropic when negotiating exit clauses for their R&D collaborations with biotechs, according to David Thompson, Eli Lilly & Co.'s VP of corporate business development, after surveying some 60 biotech termination clauses. But they often are.